Abstract Library

#2292 PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort

Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van der Zwan W

Authors: Van der Zwan W, Brabander T, Kam B, Teunissen J, Krenning E,

Keywords: Salvage, PRRT, Re-treatment, GEP-NET, Safety, Efficacy, 177Lu-DOTATATE,

#2286 A Randomized Controlled Study Comparing Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEPNET) with 177Lu-DOTATATE Alone and in Combination with Capecitabine

Introduction: PRRT with 177Lu-DOTATATE (LuTate) is an effective treatment option in patients with metastatic or inoperable GEP-NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van der Zwan W

Authors: Van der Zwan W, Wyld D, Brabander T, Teunissen J, Kam B,

Keywords: PRRT, 177Lu-DOTATATE, Capecitabine, Xeloda, PFS, OS, Toxicity, GEP-NET, RCT, Randomized,

#1578 Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors

Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Berardi R

Authors: Berardi R, Torniai M, Pusceddu S, Spada F, Brizzi M,

Keywords: pNET, dose intensity, targeted therapy, everolimus, cumulative dose,

#1534 Personalized 177Lu-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) Allows a Safe and Significant Increase of Radiation Dose to Neuroendocrine Tumors (NETs)

Introduction: 177Lu-octreotate PRRT is commonly administered at fixed/empiric activity per cycle, which results in highly variable radiation doses to critical organs and undertreatment of the majority of patients.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Del Prete M, Buteau F, Beauregard J,

Keywords: personalized, PRRT, neuroendocrine tumors ,

#840 Clinical Impact of Everolimus Cumulative Dose on Pancreatic Neuroendocrine Tumors (pNETs) Outcome

Introduction: Everolimus is approved for advanced pancreatic neuroendocrine tumors (pNETs).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Berardi R, Torniai M, Onofri A, Partelli S, Guglielmi S,

Keywords: pancreatic neuroendocrine tumor, targeted therapy, mTOR inhibitors, everolimus, cumulative dose ,